Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the transaction, the chief financial officer now directly owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Alexis Desieno also recently made the following trade(s):
- On Friday, November 15th, Alexis Desieno sold 25,118 shares of Cardlytics stock. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74.
Cardlytics Price Performance
Cardlytics stock opened at $3.49 on Tuesday. The company’s fifty day moving average price is $3.91 and its 200 day moving average price is $4.81. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52. The stock has a market capitalization of $177.37 million, a P/E ratio of -0.57 and a beta of 1.53. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.
Analyst Ratings Changes
Several equities analysts have recently weighed in on CDLX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. Evercore ISI started coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. Finally, Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cardlytics currently has an average rating of “Hold” and a consensus target price of $6.92.
View Our Latest Stock Report on Cardlytics
Institutional Investors Weigh In On Cardlytics
Several institutional investors and hedge funds have recently added to or reduced their stakes in CDLX. Atom Investors LP acquired a new position in shares of Cardlytics during the 3rd quarter valued at about $33,000. SG Americas Securities LLC purchased a new stake in Cardlytics in the 3rd quarter valued at about $45,000. Intech Investment Management LLC purchased a new stake in Cardlytics in the 3rd quarter valued at about $47,000. Quadrature Capital Ltd purchased a new stake in Cardlytics in the 3rd quarter valued at about $63,000. Finally, BNP Paribas Financial Markets raised its holdings in Cardlytics by 32.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after buying an additional 4,796 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- 3 Fintech Stocks With Good 2021 Prospects
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- What Are the U.K. Market Holidays? How to Invest and Trade
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.